

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Bleeding; hemophilia	Factor IX	<p>Mouse studies identified two human recombinant full-length factor IX variants that could be better than wild-type factor IX at treating bleeding disorders such as hemophilia. In two mouse models of bleeding disorders, vector-induced expression of either recombinant factor IX variant decreased clotting times and blood loss compared with expression of wild-type factor IX. Next steps include evaluating the effects of delivering the factor IX variants without using gene transfer approaches.</p> <p>BeneFIX, a recombinant coagulation factor IX from Pfizer Inc., is marketed to treat hemophilia. IB1001, a recombinant coagulation factor IX from Inspiration Biopharmaceuticals Inc., is under review for the same indication.</p> <p>At least five other companies have compounds targeting or based on factor IX in Phase III trials or earlier to treat hemophilia.</p> <p>SciBX 4(45); doi:10.1038/scibx.2011.1270 Published online Nov. 17, 2011</p>	Patent application filed covering use in bleeding disorders; licensed to an undisclosed company; some applications still available for licensing	<p>Milanov, P. <i>et al. Blood</i>; published online Oct. 26, 2011; doi:10.1182/blood-2011-05-353672</p> <p>Contact: Jörg Schüttrumpf, Johann Wolfgang Goethe University, Hessen, Germany e-mail: j.schuettrumpf@blutspende.de</p>